Iobenguane i 131
Azedra (iobenguane i 131) is a small molecule pharmaceutical. Iobenguane i 131 was first approved as Iobenguane sulfate i 131 on 1994-03-25.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Azedra
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| azedra | New Drug Application | 2019-03-06 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
IOBENGUANE I-131, AZEDRA, PROGENICS PHARMS INC | |||
| 2025-07-30 | ODE-204 | ||
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09I: Tumour detection radiopharmaceuticals
— V09IX: Other diagnostic radiopharmaceuticals for tumour detection in atc
— V09IX02: Iobenguane (131i)
— V10: Therapeutic radiopharmaceuticals
— V10X: Other therapeutic radiopharmaceuticals in atc
— V10XA: Iodine (131i) compounds
— V10XA02: Iobenguane (131i)
HCPCS
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 3 | 1 | — | 4 |
| Left ventricular dysfunction | D018487 | — | — | — | 1 | — | 1 | ||
| Parkinsonian disorders | D020734 | HP_0001300 | — | — | — | 1 | — | 1 | |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | — | — | — | 1 | — | 1 |
| Dementia | D003704 | F03 | — | — | — | 1 | — | 1 | |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | — | — | 1 | — | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | 10 | 14 | 4 | — | 10 | 36 | |
| Pheochromocytoma | D010673 | 3 | 5 | 2 | — | 7 | 16 | ||
| Paraganglioma | D010235 | 3 | 3 | 1 | — | 4 | 10 | ||
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 2 | 2 | 1 | — | 1 | 5 |
| Ganglioneuroblastoma | D018305 | 1 | 1 | 1 | — | — | 3 | ||
| Carcinoid tumor | D002276 | D3A.00 | 1 | — | 1 | — | — | 2 | |
| Papillary thyroid cancer | D000077273 | — | — | 1 | — | — | 1 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinoblastoma | D012175 | 1 | — | — | — | — | 1 | ||
| Thyroid neoplasms | D013964 | EFO_0003841 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | — | — | — | — | 1 | 1 |
| Ventricular tachycardia | D017180 | I47.2 | — | — | — | — | 1 | 1 | |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IOBENGUANE I 131 |
| INN | iobenguane (131i) |
| Description | Iobenguane (131I) is an organoiodine compound. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCc1cccc([131I])c1 |
Identifiers
| PDB | — |
| CAS-ID | 77679-27-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1615779 |
| ChEBI ID | — |
| PubChem CID | 71184 |
| DrugBank | DB06704 |
| UNII ID | Q461L7AK4R (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 161 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
47,726 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more